Connect with us

Health

Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021 – StreetInsider.com

MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition Pan-cancer anti-tumor activity, including in tumors exposed to prior lines…

Published

on

Article feature image

April 10, 2021 8:30 AM EDT
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premiumhere.
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition
Pan-cancer anti-tumor activity, including in tumors exposed to prior lines of therapy, seen with intermittent dosing of KB-0742
Initial safety, pharmacokinetic and pharmacodynamic data from the ongoing Phase 1/2 clinical trial for KB-0742 expected in fourth quarter…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Japan to ship 1 million Covid-19 vaccines to Vietnam on June 16 – The Kathmandu Post
Article feature image
Carbon-based antimicrobial nanoweapons to fight COVID-19 – News-Medical.Net